A case report of hemophagocytic lymphohistiocytosis secondary to tislelizumab and bevacizumab combination therapy for renal cell carcinoma
Key Points
Hemophagocytic lymphohistiocytosis occurred due to tislelizumab and bevacizumab combination therapy.
This case marks the first documented instance of HLH linked to this treatment for renal cell carcinoma.
Assessment involved detailed clinical observation of a patient with renal cell carcinoma receiving the drug combination.
These findings may indicate potential safety issues and warrant further investigation into treatment protocols.
Abstract
This study reports the first case of HLH induced by the clinically relevant combination of tislelizumab and bevacizumab in RCC, filling the gap in safety data for this first-line regimen.